retatrutide safety profile clinical trials Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide: Comprehensive Safety and Clinical
Pay in 4 interest-free payments of $5.58 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10













:max_bytes(150000):strip_icc()/Wegovy-pill-pic-590ed53ed3304ba8b2388f9d78886dae.png)

:max_bytes(150000):strip_icc()/WouldYouBeMoreLikelytoTakeGLP-1sifTheyCameinPill-Form_final-2741a721ac7748639cf0256d61df3b7f.png)








